NCT03043989 2020-02-17Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, ClarithromycinSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 Terminated4 enrolled